916 Results

Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.

Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic...

Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study.

Importance: In approximately 20% of atrial fibrillation (AF)–related ischemic strokes, stroke is the first clinical manifestation of AF. Strategies are needed to identify and therapeutically address previously undetected AF.

The Epidemiology of Atrial Fibrillation and Stroke.

The burden of stroke is increasing due to aging population and unhealthy lifestyle habits. The considerable rise in atrial fibrillation (AF) is due to greater diffusion of risk factors and screening programs.

Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.

Background: The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies. The object of this study was to quantify the...

Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis.

Hemostasis requires both platelets and the coagulation system. At sites of vessel injury, bleeding is minimized by the formation of a hemostatic plug consisting of platelets and fibrin. The traditional view of the regulation of blood...

Edoxaban: a focused review of its clinical pharmacology.

Long-term anticoagulation treatment with warfarin has been associated with a number of limitations in clinical practice and there is a need for more convenient long-term anticoagulation treatment. One of the non-vitamin K oral...

Practical management of anticoagulation in patients with atrial fibrillation.

Anticoagulation for atrial fibrillation has become more complex due to the introduction of new anticoagulant agents, the number and kinds of patients requiring therapy, and the interactions of those patients in the matrix of care.

Channelopathies.

Channelopathies are a heterogeneous group of disorders resulting from the dysfunction of ion channels located in the membranes of all cells and many cellular organelles. These include diseases of the nervous system (e.g., generalized epilepsy...

Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model.

Thirty-three million people have atrial fibrillation (AF), a disorder of heart rhythm.1 Over the past several decades, we have learned that this dysrhythmia originates in the interplay between genetic predisposition, ectopic electrical...

Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective.

The biochemical properties of the NOACs and their differences from the mechanism of action of VKAs contribute to their properties as anticoagulants. These properties include:...

Load more